Trial Profile
An open-label, randomized, single-dose, 4 period crossover relative bioavailability study comparing APC-5000 (fluticasone propionate and salmeterol xinafoate) and Advair Diskus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2015
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 05 Mar 2015 New trial record